BiondVax Announces Second Quarter 2018 Financial Results

Jerusalem, Israel - August 22, 2018 -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced its financial results for the quarter ended June 30, 2018.Second Quarter 2018 Financial SummaryResults are in New Israel Shekels (NIS) and convenience translation to $US is provided using the exchange rate of 3.65 (NIS/$US) as at June 30, 2018.

• Second quarter operating expenses were NIS 30.6m ($8.4m) compared with NIS 2.59m for the second quarter of 2017;
• Second quarter R&D expenses amounted to NIS 29.2m ($8m) compared with NIS 2m for the second quarter of 2017;

As of June 30, 2018, BiondVax had cash and cash equivalents of NIS 37.1 million ($10.1 million) as compared to NIS 36.6m as of March 30, 2018. Expenses are related to execution of planned ongoing operations including the launch of a pivotal, clinical efficacy, Phase 3 trial of the Company’s M-001 Universal Flu Vaccine candidate, and construction of a mid-size commercial manufacturing facility.About BiondVax BiondVax (NASDAQ: BVXV) is a Phase 3 clinical stage biopharmaceutical company developing a universal flu vaccine. The vaccine candidate, called M-001, is designed to provide multi-season protection against current and future, seasonal and pandemic influenza virus strains. BiondVax’s proprietary technology utilizes a unique combination of conserved and common influenza virus peptides, activating both arms of the immune system for a cross-protecting and long-lasting effect. In a total of 6 completed Phase 1/2 and Phase 2 human clinical trials, covering 698 participants, the vaccine has been shown to be safe, well-tolerated, and immunogenic. Please visit www.biondvax.com.Contact Details: Joshua E. Phillipson | +972 8 930 2529 | j.phillipson@biondvax.comForward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties reflect the management’s current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, the prosecution and outcome of the ongoing Phase 2 and Phase 3 trials and any subsequent trials; timing of receipt of regulatory approval of the new manufacturing facility its products; ability to demonstrate the efficacy and safety of the vaccine; the timing of clinical trials and marketing approvals; the risk that drug development involves a lengthy and expensive process with uncertain outcome; the ability of the Company to maintain, preserve and defend its intellectual property and patents granted; whether our  vaccine candidate will successfully advance through the clinical trial process on a timely basis, or at all, and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; the adequacy of available cash resources and the ability to raise capital when needed. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2017 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC’s website, www.sec.gov, and in the Company’s periodic filings with the SEC and the Tel-Aviv Stock Exchange. We undertake no obligation to revise or update any forward-looking statement for any reason.

 ** Tables to Follow **

BALANCE SHEETS
In thousands, except per share data
								Conveniencetranslation
		December 31,		June 30,				June 30,
		2017		2017		2018		2018
		Audited		Unaudited				Unaudited
		N I S						U.S. dollars
CURRENT ASSETS:
Cash and cash equivalents		71,382		31,334		37,128			10,172
Marketable securities		-		4,067					-
Short-term deposits		-		1,200		-			-
Other receivables		3,923		2,812		4,067			1,114
		75,305		39,413		41,195			11,286
LONG‑TERM ASSETS:
Property, plant and equipment		5,510		1,233		18,793			5,149
Other long term assets		880		505		880			241
		6,390		1,738		19,673			5,390
		81,695		41,151		60,868			16,676
CURRENT LIABILITIES:
Trade payables		6,223		1,188		1,323			363
Other payables		660		664		780			214
		6,883		1,852		2,103			577
LONG‑TERM LIABILITIES:
Liability in respect of government grants		10,300		-		12,790			3,504
Loan from others		-		-		20,710			5,674
Warrants		8,177		18,231		8,475			2,322
Severance pay liability, net		83		79		79			22
		18,560		18,310		42,054			11,522
SHAREHOLDERS' EQUITY:
Ordinary shares of NIS 0.0000001 par value:
Authorized: 391,000,000 shares as of June 30,2018, 2017 (unaudited) and December 31,2017; Issued and Outstanding: 261,419,599,179,595,199 and 261,419,599 shares respectively		*) -		*)   -		*) -			*) -
Share premium		179,669		132,824		179,821			49,265
Options		-		533		-			-
Other comprehensive income		-		2		-			-
Accumulated deficit		(123,417)		(112,370)		(163,110)			(44,688)
		56,252		20,989		16,711			4,577
		81,695		41,151		60,868			16,676
*)            Represents an amount lower than NIS 1.

STATEMENTS OF COMPREHENSIVE INCOME
In thousands, except per share data
																		Convenience translation
		Year ended December 31,					Three months ended June 30,					Six months ended June 30,						Six months ended June 30,
		2017					2017		2018			2017			2018			2018
							Unaudited											Unaudited
		N I S																U.S. dollars
		(In thousands, except per share data)
Operating expenses:
Research and development, net of   participations			18,777			2,022			29,205				3,896			40,950		11,219
Marketing, general and administrative			4879			569			1,445				1,663			2,329		638
Total operating expenses			23,656			2,591			30,650				5,559			43,279		11,857
Operating loss			(23,656)			(2,591)			(30,650)				(5,559)			(43,279)		(11,857)
Financial income			18			5			6,386				13			6,386		1,255
Financial expense			(10,913)			(9,086)			(1,227)				(17,958)			(2,800)		(273)
			0
Total finance (expense) income, net			(10,895)			(9,081)			5,159				(17,945)			3,586		982
Net loss			(34,551)			(11,672)			(25,491)				(23,504)			(39,693)		(10,875)
Other comprehensive loss:
Items to be reclassified to profit or loss in subsequent periods:
Loss from available-for-sale financial assets			(6)			(4)			-				(4)			-		-
Total comprehensive loss			(34,557)			(11,676)			(25,491)				(23,508)			(39,693)		(10,875)
Basic and diluted net loss per share (NIS)			(0.17)			(0.07)			(0.10)				(0.14)			(0.15)		(0.04)
Weighted average number of shares outstanding used to compute basic anddiluted loss per share			201,030,768			175,809,413			261,419,599				169,182,101			261,419,599		261,419,599